SELF-MEDICATION WITH GLP-1 ANALOGS: CLINICAL RISKS AND THE PHARMACIST’S ROLE IN RATIONAL USE
DOI:
https://doi.org/10.56238/arev8n4-040Keywords:
GLP-1 Analogs, Self-Medication, Irrational Use, Patient Safety, Pharmaceutical CareAbstract
Given the increasing use of GLP-1 analogs for cosmetic purposes and outside of clinical indications, it is important to understand the risks associated with self-medication and the inappropriate use of these drugs, as such practices can harm patients. The objective of this study was to assess the main risks associated with the use of these medications, as well as to analyze the role of pharmacists in promoting their safe and rational use. To this end, an integrative literature review was conducted in databases using pre-defined selection criteria. A total of 22 scientific articles were analyzed, and the results showed that gastrointestinal effects are the most frequently reported among users, in addition to the occurrence of more serious adverse events, such as ketoacidosis, pancreatitis, and neurological disorders. It was also found that pharmacist supervision is essential, as it helps guide patients, promotes safe use, and helps reduce inappropriate practices. Finally, although this class of medications offers benefits in the treatment of obesity, their use without proper supervision can pose significant risks, underscoring the need for further studies and professional monitoring to ensure long-term safety.
Downloads
References
ASHRAF, Amir Reza; MACKEY, Tim Ken; VIDA, Róbert György; et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research, v. 26, p. e65440, 2024. DOI: https://doi.org/10.2196/65440
BAYRAM-OZGUR, Dilara; DEMIRTÜRK, Ecenur; SAR, Yigitcan. Community Pharmacists’ Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study. Diabetes, Metabolic Syndrome and Obesity, v. 19, p. 587750, 2026. DOI: https://doi.org/10.2147/DMSO.S587750
BODANOWITZ, Jonas Michael; MATTES, Isabell; LOEBERMANN, Micha; et al. Case Report: Rhabdomyolysis following initiation of tirzepatide. Frontiers in Pharmacology, v. 16, 2025. DOI: https://doi.org/10.3389/fphar.2025.1660785
CASELLA, Sarah; GALLI, Katelyn. Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists? Journal of Pharmacy Technology, v. 40, n. 2, p. 108–111, 2024. DOI: https://doi.org/10.1177/87551225231216638
CHIAPPINI, Stefania; VICKERS-SMITH, Rachel; HARRIS, Daniel; et al. Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FAERS Pharmacovigilance Dataset. Pharmaceuticals, v. 16, n. 7, p. 994, 2023. DOI: https://doi.org/10.3390/ph16070994
COLLINS, Logan; COSTELLO, Ryan A. Glucagon-Like Peptide-1 Receptor Agonists. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2026.
CROCETTA, Nicholas; GUAY, Kyle; WATSON, Alexandra. Evaluation of a pharmacist’s impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting. Family Practice, v. 40, n. 2, p. 255–260, 2023. DOI: https://doi.org/10.1093/fampra/cmac110
DAI, Hao; LI, Yongqiu; LEE, Yao An; et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncology, v. 11, n. 10, p. 1186–1193, 2025. DOI: https://doi.org/10.1001/jamaoncol.2025.2681
EUROPEAN MEDICINES AGENCY (EMA). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8–11 July 2024. 2024.
EUROPEAN MEDICINES AGENCY (EMA). PRAC concludes that NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy). 2026.
FILIPPATOS, Theodosios D.; PANAGIOTOPOULOU, Thalia V.; ELISAF, Moses S. Adverse Effects of GLP-1 Receptor Agonists. Review of Diabetic Studies, v. 11, n. 3, p. 202–230, 2014. DOI: https://doi.org/10.1900/RDS.2014.11.202
GAW, Christopher E.; HAYS, Hannah L.; KEMP, Cydney A.; et al. Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022. Journal of Medical Toxicology, v. 20, n. 2, p. 193–204, 2024. DOI: https://doi.org/10.1007/s13181-024-00999-x
GUIRGUIS, A.; CHIAPPINI, S.; PAPANTI, G. D.; et al. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments. European Neuropsychopharmacology, v. 82, p. 82–91, 2024. DOI: https://doi.org/10.1016/j.euroneuro.2024.02.003
IQBAL, Pathan Mohamad Rafe; MAADARANI, Ossama Sajeh; BITAR, Zouheir Ibrahim. Tirzepatide-induced ketoacidosis in non-diabetic patients. European Journal of Case Reports in Internal Medicine, v. 11, n. 4, 2024. DOI: https://doi.org/10.12890/2024_004357
ISHØY, Pelle L.; KNOP, Filip K.; BROBERG, Brian V.; et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia. Diabetes, Obesity and Metabolism, v. 19, n. 2, p. 162–171, 2017. DOI: https://doi.org/10.1111/dom.12795
JADVANI, Rutvikkumar; SINGH, Meenu. From weight loss to muscle loss: rhabdomyolysis linked to semaglutide. Clinical Kidney Journal, v. 18, n. 12, p. sfaf356, 2025. DOI: https://doi.org/10.1093/ckj/sfaf356
LUIZA, Vera Lucia; MENDES, Luiz Villarinho Pereira; TAVARES, Noemia Urruth Leão; et al. Inappropriate use of medicines and associated factors in Brazil. Health Policy and Planning, v. 34, n. Suppl 3, p. iii27–iii35, 2019. DOI: https://doi.org/10.1093/heapol/czz038
MANDO, Nur; THOMSON, Erica; FOWLER, Matthew; et al. Acute Pancreatitis Caused by Tirzepatide. Cureus, v. 16, n. 12, p. e76007, 2024. DOI: https://doi.org/10.7759/cureus.76007
MASSY, Marine; MARTI, Stefanie; HAMMER, Helly; et al. Increased vision impairment reports linked to semaglutide. BMC Medicine, v. 23, p. 203, 2025. DOI: https://doi.org/10.1186/s12916-025-04031-z
MHRA (Medicines and Healthcare products Regulatory Agency). GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. Drug Safety Update, 2026.
MODESTINO, Edward J.; BOWIRRAT, Abdalla; LEWANDROWSKI, Kai-Uwe; et al. Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist. Acta Scientific Neurology, v. 7, n. 5, p. 12–18, 2024. DOI: https://doi.org/10.31080/ASNE.2024.07.0731
MUSCHLER, Karen; MUSCHALEK, Rachael; HOYTE, Christopher. Characterization of GLP-1 agonist exposures reported to a poison center. Clinical Toxicology, v. 63, n. 2, p. 133–136, 2025. DOI: https://doi.org/10.1080/15563650.2024.2444642
ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE (OPAS/OMS). OMS publica diretriz global sobre uso de medicamentos agonistas de GLP-1 para tratamento da obesidade. 2025.
OSEI, Samuel Prince; AKOMANING, Edwin; FLORUT, Teodora Francesca; et al. Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists. Diagnostics, v. 14, n. 24, p. 2829, 2024. DOI: https://doi.org/10.3390/diagnostics14242829
PI-SUNYER, Xavier; ASTRUP, Arne; FUJIOKA, Ken; et al. A Randomized Controlled Trial of Liraglutide in Weight Management. New England Journal of Medicine, v. 373, n. 1, p. 11–22, 2015. DOI: https://doi.org/10.1056/NEJMoa1411892
RODRIGUES, Marília Barreto; SILVA, Thiago Dos Santos Da; EMILIANO, William Da Silva, O uso off-label da semaglutida (Ozempic®) para emagrecimento e a atenção farmacêutica na dispensação, Brazilian Journal of Health Review , v. 1, pág. e76780, 2025. DOI: https://doi.org/10.34119/bjhrv8n1-165
SCAGLIUSI, Fernanda Baeza et al , O território desconhecido dos novos medicamentos para obesidade em usuários sem obesidade: uma perspectiva sociomédica, Obesity , p. oby.70069, 2025.
WILDING, John P. H.; BATTERHAM, Rachel L.; DAVIES, Melanie; et al. Weight regain after withdrawal of semaglutide. Diabetes, Obesity and Metabolism, v. 24, n. 8, p. 1553–1564, 2022. DOI: https://doi.org/10.1111/dom.14725
ZHAO, Tao; ZHENG, Liting; FENG, Yiyun; et al. Association between semaglutide dosage forms and ocular adverse events. BMC Ophthalmology, v. 25, n. 1, p. 248, 2025. DOI: https://doi.org/10.1186/s12886-025-04096-7
ZHOU, Yu; CHEN, Mingyu; LIU, Libin; et al. Gastrointestinal risk associated with GLP-1 receptor agonists. Diabetes, Metabolic Syndrome and Obesity, v. 15, p. 155–163, 2022. DOI: https://doi.org/10.2147/DMSO.S348025
